Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LUNG
stocks logo

LUNG

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
21.73M
-8.57%
-0.385
+16.67%
22.65M
+0.48%
-0.340
-5.56%
23.06M
-3.35%
-0.332
-12.63%
Estimates Revision
The market is revising Downward the revenue expectations for Pulmonx Corporation (LUNG) for FY2025, with the revenue forecasts being adjusted by -0.83% over the past three months. During the same period, the stock price has changed by 22.99%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.83%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-5.39%
In Past 3 Month
Stock Price
Go Up
up Image
+22.99%
In Past 3 Month
Wall Street analysts forecast LUNG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LUNG is 4.10 USD with a low forecast of 2.50 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast LUNG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LUNG is 4.10 USD with a low forecast of 2.50 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
2 Hold
0 Sell
Moderate Buy
Current: 2.140
sliders
Low
2.50
Averages
4.10
High
6.00
Current: 2.140
sliders
Low
2.50
Averages
4.10
High
6.00
Lake Street
Buy
downgrade
$8 -> $4
2025-10-28
Reason
Lake Street
Price Target
$8 -> $4
2025-10-28
downgrade
Buy
Reason
Lake Street lowered the firm's price target on Pulmonx to $4 from $8 and keeps a Buy rating on the shares. While the return of former CEO Glen French and CFO Derrick Sung was "certainly surprising," the firm believes the Street will view the return of prior leadership positively, the analyst tells investors. The firm, which continues to think shares are attractive given the "vast clinical verification/proof of concept of Zephyr valves," and the market opportunity and new product pipeline, notes that its lowered price target still "supports an approximate double from after-hours prices."
Citi
Neutral
downgrade
2025-05-22
Reason
Citi
Price Target
2025-05-22
downgrade
Neutral
Reason
Citi lowered the firm's price target on Pulmonx to $4.15 from $6.50 and keeps a Neutral rating on the shares. The firm updated models in medical technology following the Q1 reports. The good news is that underlying sector fundamentals appear intact, including volumes, pricing, and capex, the analyst tells investors in a research note.
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$17
2025-03-11
Reason
D. Boral Capital
Jason Kolbert
Price Target
$17
2025-03-11
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Initiates
$17
2025-03-10
Reason
D. Boral Capital
Jason Kolbert
Price Target
$17
2025-03-10
Initiates
Strong Buy
Reason
Citigroup
Joanne Wuensch
Strong Buy
to
Hold
Downgrades
$17 → $7.5
2024-12-11
Reason
Citigroup
Joanne Wuensch
Price Target
$17 → $7.5
2024-12-11
Downgrades
Strong Buy
to
Hold
Reason
Wells Fargo
Larry Biegelsen
Hold
Maintains
$10 → $8
2024-12-11
Reason
Wells Fargo
Larry Biegelsen
Price Target
$10 → $8
2024-12-11
Maintains
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Pulmonx Corp (LUNG.O) is -1.53, compared to its 5-year average forward P/E of -12.19. For a more detailed relative valuation and DCF analysis to assess Pulmonx Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-12.19
Current PE
-1.53
Overvalued PE
-0.30
Undervalued PE
-24.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-12.46
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.06
Undervalued EV/EBITDA
-26.97

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
10.87
Current PS
0.00
Overvalued PS
22.37
Undervalued PS
-0.62
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 1169.71% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

LUNG News & Events

Events Timeline

(ET)
2025-11-12
16:47:50
Pulmonx lowers FY25 revenue forecast to $89M-$90M, down from $90M-$92M
select
2025-11-12
16:46:34
Pulmonx Announces Q3 Earnings Per Share of 34 Cents, Below Consensus Estimate of 42 Cents
select
2025-10-27 (ET)
2025-10-27
16:12:04
Pulmonx Announces Preliminary Q3 Revenue of $21.5M, Exceeding Consensus of $20.78M
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-04Globenewswire
Pulmonx Grants 1.625 Million Equity Awards to Attract Executives
  • Executive Incentive Plan: On December 1, 2025, Pulmonx granted 1.625 million equity awards to attract new executives, including the CFO and COO, reflecting the company's commitment to strengthening its leadership team and enhancing management stability.
  • Restricted Stock Units Allocation: Of the total, 1.225 million shares are restricted stock units (RSUs), with CFO Derrick Sung receiving 1.2 million shares, and these awards will vest over four years, aimed at increasing employee retention and incentivizing long-term contributions.
  • Performance Stock Units Incentive: Mr. Sung also received performance stock units (PSUs) for up to 400,000 shares, with vesting contingent on both time and performance metrics, designed to align executive incentives with company performance and drive higher achievement levels.
  • Compliance of Incentive Plan: The equity awards comply with Nasdaq listing rules, indicating Pulmonx's strategic focus on attracting and retaining talent, which is expected to enhance the company's appeal in the competitive healthcare sector.
[object Object]
Preview
5.0
12-04Newsfilter
Pulmonx Grants 1.625 Million Equity Awards to Attract Executives
  • Equity Incentive Plan: On December 1, 2025, Pulmonx granted 1.625 million shares of common stock under its 2025 Inducement Plan to attract new executives, including the CFO and COO, highlighting the company's commitment to talent acquisition.
  • Restricted Stock Units: The new executives received a total of 1.225 million RSUs, with CFO Derrick Sung receiving 1.2 million, designed to ensure long-term retention through a gradual vesting schedule, thereby enhancing management stability.
  • Performance Stock Units: Derrick Sung also received a PSU award for up to 400,000 shares, contingent on meeting both time and performance conditions, indicating the company's focus on aligning executive performance with long-term objectives.
  • Inducement Plan Context: This inducement plan is specifically designed for individuals who were not previously employed by Pulmonx, in accordance with Nasdaq Listing Rule 5635(c)(4), aiming to attract top talent through appealing equity incentives and further solidifying the company's leadership in the treatment of chronic obstructive pulmonary disease.
[object Object]
Preview
9.5
11-13NASDAQ.COM
Pulmonx Corporation (LUNG) Posts Q3 Loss but Exceeds Revenue Projections

  • Earnings Performance: Pulmonx Corporation reported a quarterly loss of $0.34 per share, better than the expected loss of $0.40, marking a 15% earnings surprise. The company has surpassed consensus EPS estimates in all four recent quarters.

  • Revenue Growth: The company generated revenues of $21.5 million for the quarter, exceeding the Zacks Consensus Estimate by 4.1% and showing an increase from $20.39 million a year ago.

  • Stock Outlook: Despite underperforming the market with a 69.2% decline in shares this year, Pulmonx holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market. Future stock movements will depend on earnings estimate revisions.

  • Industry Context: The Medical Info Systems industry, where Pulmonx operates, is currently ranked in the top 20% of Zacks industries, suggesting a favorable environment for stocks in this sector.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Pulmonx Corp (LUNG) stock price today?

The current price of LUNG is 2.14 USD — it has increased 13.23 % in the last trading day.

arrow icon

What is Pulmonx Corp (LUNG)'s business?

Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.

arrow icon

What is the price predicton of LUNG Stock?

Wall Street analysts forecast LUNG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LUNG is 4.10 USD with a low forecast of 2.50 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Pulmonx Corp (LUNG)'s revenue for the last quarter?

Pulmonx Corp revenue for the last quarter amounts to 21.50M USD, increased 5.47 % YoY.

arrow icon

What is Pulmonx Corp (LUNG)'s earnings per share (EPS) for the last quarter?

Pulmonx Corp. EPS for the last quarter amounts to -0.34 USD, decreased -5.56 % YoY.

arrow icon

What changes have occurred in the market's expectations for Pulmonx Corp (LUNG)'s fundamentals?

The market is revising Downward the revenue expectations for Pulmonx Corporation (LUNG) for FY2025, with the revenue forecasts being adjusted by -0.83% over the past three months. During the same period, the stock price has changed by 22.99%.
arrow icon

How many employees does Pulmonx Corp (LUNG). have?

Pulmonx Corp (LUNG) has 291 emplpoyees as of December 05 2025.

arrow icon

What is Pulmonx Corp (LUNG) market cap?

Today LUNG has the market capitalization of 88.27M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free